Could a simple cream boost eczema relief?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female subject. 2. Aged 18 or more. 3. With mild to moderate atopic dermatitis based on the Investigator's Global Assessment for Atopic Dermatitis (IGA-AD). 4. Presence of two comparable atopic dermatitis lesions requiring treatment with topical corticosteroids, located at anatomically distant sites. 5. Having given her/his informed, written consent, 6. Cooperative, fully informed of the treatment procedures, and aware of the importance and schedule of follow-up visits, ensuring expected full adherence to the study protocol. 7. Psychologically capable of understanding the study information and providing informed consent. 8. Affiliated to a health social security system. 9. Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after the study end and must have a negative urine pregnancy test before the first treatment. Exclusion Criteria: 1. Subject currently participating in another clinical study that may interfere with the assessments of the present study, according to the investigator's judgment. 2. Subject unable to understand the information provided - including study procedures - due to linguistic or psychiatric reasons, and therefore unable to give written informed consent or to complete the study diary as required. 3. Subject who, in the investigator's judgment, is unlikely to comply with study-related constraints and requirements. 4. Subject who has forfeited his/her freedom by administrative or legal decision, or who is under legal guardianship. 5. Female subject of childbearing potential who is pregnant, breastfeeding, or planning to become pregnant during the study. 6. Subject with a known contraindication to topical corticosteroids, such as hypersensitivity to desonide, betamethasone, or any component of the prescribed corticosteroid formulations. 7. Subject with broken or ulcerated skin, acne, rosacea (including perioral dermatitis), any untreated or active skin infection (viral, bacterial, or fungal), or skin thinning at the application sites. 8. Subject with a skin disease, abnormality, or dermatological condition in the study area that may interfere with study assessments. 9. Subject with acute, chronic, or progressive disease, or relevant medical history, considered by the investigator to be hazardous for the subject, incompatible with the study, or likely to interfere with study assessments. 10. Any systemic treatment, including oral corticosteroids, that is incompatible with the study or likely to interfere with study assessments according to the investigator, administered in the weeks prior to the inclusion visit, ongoing, or planned to start during the study. 11. Any topical treatment on the tested area that is incompatible with the study or likely to interfere with study assessments according to the investigator, administered in the weeks prior to the inclusion visit.